Cirrus Therapeutics has expanded into Singapore with a new R&D site and formed a partnership with A*STAR to advance ophthalmic therapies targeting chronic blinding diseases in the Asia-Pacific region.

• Expansion: Establishes a Singapore R&D site and appoints a site head to support regional research and development activities.
• Collaboration: Partners with A*STAR to accelerate development of ophthalmic assets, including pipeline programmes in ocular immunology.
• Pipeline: Advances a retinal pigment epithelium (RPE) cell therapy for geographic atrophy alongside a gene therapy programme targeting age-related macular degeneration.

This summary is based on a news article by BioSpectrum Asia.

Image for illustrative purposes only. Source: Canva.